Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Brucea javanica oil emulsion induces autophagy in glioma cells via lncRNA-p21/miR-17-5p/PTEN pathway
Abstract
Purpose: To investigate the possible effects of Brucea javanica oil emulsion in the progression of glioma, and elucidate the possible regulatory mechanism.
Methods: MTT assays were performed to assess the effects of BJOE on the viability of glioma cells, and flow cytometry (FCM) was conducted to evaluate its effect of the oil on cell apoptosis. Immunoblot assays were carried out to investigate its effects on glioma cell autophagy and LincRNA-p21/miR-17-5p/PTEN axis of glioma cells.
Results: Administration of BJOE (1, 2 and 4 mg/mL) increased the protein levels of LC3 II/ LC3 I and Beclin-1, but decreased the protein levels of p62 (p < 0.05). These changes were reversed by knockdown PTEN. Moreover, the expression of lncRNA-p21 and PTEN mRNA were significantly elevated, while the expression of miR-17-5p significantly decreased in BJOE-treated U251MG cells (p < 0.05).
Conclusion: BJOE may serve as a novel therapeutic drug for the treatment of glioma; The antitumor effect of BJOE is based on its ability to regulate lncRNA-p21/miR-17-5p/PTEN pathway.
